This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

The Hutchinson Santé G-VIR® Glove Reduces The Risk Of HIV Virus Transmission In Accidental Needlesticks By 99%, According To A Study Published In The Journal Surgery In February 2013[1]

LIANCOURT, France, February 26, 2013 /PRNewswire/ --

The AIDS and hepatitis C viruses expose healthcare personnel to the risk of viral transmission (see the section Accidental exposure to blood:  the contamination  risks for healthcare personnel) as a result of:

  • accidental injuries during treatment (needles, scalpels, lancets, bone fragments, etc.)
  • contact with body fluids that contain blood

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/58703-Hutchinson-Sante

Thanks to a new patented technology developed by Hutchinson Santé, an innovative player in the fight against infection risks and in the comfort of healthcare personnel, the G-VIR® glove reduces the risk of contamination in cases of accidental exposure to blood, as shown in the study published in the February edition of  Surgery    (read the opinion of Prof. Charles Edmiston, surgeon and epidemiologist in  - Milwaukee, United States-, co-author of the article).

The G-VIR® is an active protection glove, designed and developed to improve protection for carers against the risks of viral contamination. The G-VIR® is made up of 3 layers. The middle layer includes a disinfecting liquid dispersed as micro-droplets (see: G-VIR®, innovative technology for protecting carers): in the case of an accidental puncture, the disinfecting liquid is released on the inside and the outside of the sharp to inactivate the viruses.

The study presented in  Surgery   - the abstract of which    is attached  -    is t he first to test the efficacy  of the G-VIR® in reducing the transmission of the AIDS virus - the studies carried out up to now had assessed the G-VIR®'s performance on a number of model viruses, such as BVDV, FIV, and HSV1 [ 2] but never on HIV.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs